Davita Inc vs ProShares UltraShort Bloomberg Natural Gas ETF — how do they compare? Davita Inc trades at $179.25 (market cap $11.29B), while ProShares UltraShort Bloomberg Natural Gas ETF trades at $24.75 (market cap $141.25M). The key difference: Davita Inc is far larger — about 79.9× ProShares UltraShort Bloomberg Natural Gas ETF's market cap, and Davita Inc is trading nearer its 52-week high, ProShares UltraShort Bloomberg Natural Gas ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Davita Inc for 114 Days and ProShares UltraShort Bloomberg Natural Gas ETF for 10 Days on average.
| DVA | KOLD | |
|---|---|---|
Market Cap | $11.29B | $141.25M |
Volume | 582,204 | 5,492,367 |
Sector | Health | Leveraged / Inverse |
52-Week High | $240.96 | $49.39 |
52-Week Low | $103.87 | $13.58 |
Typical Hold Time | 114 Days | 10 Days |
Enterprise Value | $24.01B | — |
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $179.25, up 1.4% with strong earnings momentum after beating estimates for three consecutive quarters. The stock shows mixed technical signals with bearish moving averages but neutral oscillators, trading near resistance at $179. Fundamentally, revenue growth continues with 2025 revenue reaching $13.64B, though net margins compressed to 5.47% from 7.3% in 2024. Recent partnership expansion with Humana for value-based kidney care represents significant growth opportunity.
Outlook remains positive with analyst consensus target of $235.67 implying 31% upside, though elevated debt levels and regulatory risks require monitoring. The company benefits from demographic tailwinds in kidney care services and strong institutional support, including Berkshire Hathaway's 45% stake, providing stability amid market volatility.
KOLD trades at $24.75, down 0.36% with bearish technical signals from moving averages. The stock faces pressure from record-high natural gas production and mild weather forecasts, though geopolitical tensions in the Middle East provide some support. Technical indicators show oversold conditions with RSI at 31.97, while support levels are established at $23-$25.
The outlook remains cautious with bearish technical momentum and fundamental headwinds from oversupply concerns. Near-term catalysts include geopolitical developments and winter demand, but elevated production levels and storage capacity constraints present significant downside risks for energy sector investors.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →KOLD is an inverse leveraged ETF that seeks to provide two times (2x) the inverse daily performance of the Bloomberg Natural Gas Subindex. It is designed for investors looking to profit from falling natural gas prices.
Read more on KOLD →